A vaccine against SARS-COV-2: Repurposing the Influenza A (H1N1)/Flu vaccine into a Prophylactic Flu-COVID-19 vaccine: Influenza A (H1N1)/Flu vaccine inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 5/April/2020, 3.14 pm

A vaccine against SARS-COV-2: Repurposing the tuberculosis BCG vaccine into a Prophylactic COVID-19 vaccine: BCG vaccine inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 1/April/2020, 1.29 am
March 31, 2020
A potential vaccine against SARS-COV-2: Repurposing the IB-ND Virus-like particles (VLPs) vaccine  into a Prophylactic IB-ND VLPs-COVID-19 vaccine: A novel chimeric infectious bronchitis-Newcastle disease (IB-ND) virus-like particles (VLPs) inhibit SARS-COV-2/1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 12/April/2020, 11.01 pm
April 12, 2020
Show all

Introduction: What they say:

A study from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Charlestown, MA 02129, USA shows that “The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.” This study was published, in the 24 December 2009 issue of the journal “Cell” (the number 1 research journal in General Biology with an impact factor of 33),  by the 2015 Laskar award winner Prof. Stephen Elledge, Brass and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: A vaccine against SARS-COV-2: Repurposing the Influenza A (H1N1)/Flu vaccine into a Prophylactic Flu-COVID-19 vaccine: Influenza A (H1N1)/Flu vaccine inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 5/April/2020, 3.14 pm


What is known?

Prof. Stephen Elledge research team has showed that interferon-inducible transmembrane proteins IFITM1, 2, and 3 inhibit  influenza A H1N1 virus, West Nile virus, and dengue virus replication, suggesting that increasing the expression of IFITM3 may confer resistance against these viruses. Other studies suggest that IFITM3 may also protect against Ebola virus, hepatitis C virus, yellow fever virus and SARS coronavirus etc.


From research findings to therapeutic opportunity: 

This study suggests, for the first time, that Influenza A (H1N1)/Flu  vaccine-based therapy, with detailed mechanistic insights, for COVID-19 and other infectious diseases. Influenza A (H1N1)/Flu  vaccine, by increasing the expression of its target genes, it may increase the expression of interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides. Thereby, it may: (1) inhibit the replication of  SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses; (2) confer resistance against  infection caused by SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Foot and Mouth disease, ADV, Influenza H1NI1,  respiratory syncytical,  Sindbis, and SFV viruses; and (3) promote innate immunity (Figure 1) Thus, pharmacological formulations encompassing ” Influenza A (H1N1)/Flu vaccine, either alone or in combination with other drugs/compounds, can be used to prevent/treat/protect against infections caused by SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Foot and Mouth disease, ADV (Adenovirus), Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses (Figure 2).

This image has an empty alt attribute; its file name is Influenza-A-H1N1-Vaccine-aids-in-attenuation-of-SARS-coronavirus1-and-2-production1--770x578.jpg

Figure 1. Mechanistic insight into how Influenza A (H1N1)/Flu vaccine prevent/protect against SARS-COV-2. Influenza A (H1N1)/Flu vaccine inhibits SARS-COV-2 &  SARS-COV-1 through induction of its target genes, such as antiviral Proteins IFITM3, Interferon-stimulated gene 15, Mx2, and others.

This image has an empty alt attribute; its file name is Influenza-A-H1N1-Vaccine-aids-in-attenuation-of-SARS-coronavirus1-and-2-production1-1-1.jpg2_-1-770x578.jpg

Figure 2 Mechanistic insight into how Influenza A (H1N1)/Flu vaccine functions as a broad spectrum anti-infective agent. Influenza A (H1N1)/Flu vaccine inhibits SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial , Sindbis, Foot and Mouth disease virus, ADV, and SFV viruses production through induction of its target genes, such as antiviral Proteins IFITM3, Interferon-stimulated gene 15, Mx2 and others.

This image has an empty alt attribute; its file name is Influenza-A-H1N1-Vaccine-aids-in-attenuation-of-SARS-coronavirus1-and-2-production1-.jpg3_-770x578.jpg

Figure 3.  Influenza A (H1N1)/Flu can function as a broad-spectrum anti-infective agent.

 

This image has an empty alt attribute; its file name is Influenza-A-H1N1-Vaccine-aids-in-attenuation-of-SARS-coronavirus1-and-2-production1-.jpg4_-770x578.jpg

Figure 4.  Influenza A (H1N1)/Flu can prevent/treat/protect against SARS-COV-2.

 

This image has an empty alt attribute; its file name is Influenza-A-H1N1-Vaccine-aids-in-attenuation-of-SARS-coronavirus1-and-2-production1-.jpg5_-770x578.jpg

Figure 5.  Repurposing the Influenza A (H1N1)/Flu into a SARS-COV-2 (Flu-SARS-COV vaccine) vaccine. GBMD (genomediscovery.org) is looking for Scientists/Professor/Medical faculties who would be interested in collaborating with us.


Details of the research findings: 

Idea formulated by Dr L Boominathan PhD

Undisclosed information: How Influenza A (H1N1)/Flu increases the expression of antiviral Protein IFITM3, Interferon-stimulated gene 15, & Mx2

Type: Research cooperation

For more details on research cooperation, you may reach us at drboomi@genomediscovery.org or admin@genomediscovery.org


References: 

CitationBoominathan L, A vaccine against SARS-COV-2: Repurposing the Influenza A (H1N1)/Flu vaccine into a Prophylactic Flu-COVID-19 vaccine: Influenza A (H1N1)/Flu vaccine inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 5/April/2020, 3.08 pm, and others 5/April/2020, 3.14 am

Courtesy: When you cite drop us a line at info@genomediscovery.org,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Comments are closed.